VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

rMVA-SIV-CD40L
Vaccine Information
  • Vaccine Name: rMVA-SIV-CD40L
  • Target Pathogen: Human Immunodeficiency Virus
  • Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
  • Vaccine Ontology ID: VO_0004792
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector: Modified Vaccinia Ankara (MVA) virus vaccine vector
  • Preparation: Co-expressed the CD40L with our DNA/SIV vaccine such that the CD40L is anchored on the membrane of SIV virus-like particle (VLP) (Kwa et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Macaque Response

  • Vaccination Protocol: The macaques were divided into 3 groups and group 1 was vaccinated with a DNA/MVA SIV vaccine, group 2 was vaccinated with the DNA/MVA SIV vaccine with CD40L in the DNA, and the third group was an unvaccinated control (Kwa et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The macaques were intrarectally challenged with SIVE660 at a dose of 5000 TCID to test the level of protection of the vaccines (Kwa et al., 2014).
  • Efficacy: CD40L adjuvant enhanced the functional quality of anti-Env antibody response and breadth of anti-SIV CD8 and CD4 T cell responses, significantly delayed the acquisition of heterologous mucosal SIV infection and improved viral control. Notably, the CD40L adjuvant enhanced the control of viral replication in the gut at the site of challenge that was associated with lower mucosal CD8 immune activation, one of the strong predictors of disease progression (Kwa et al., 2014).
References
Kwa et al., 2014: Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR. CD40L-adjuvanted DNA/MVA SIV239 vaccine enhances SIV-specific humoral and cellular immunity, and improves protection against a heterologous SIVE660 mucosal challenge. Journal of virology. 2014; ; . [PubMed: 24920805].